Cargando…

Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is extremely aggressive and associated with poor prognosis. There are no known predictive or prognostic markers for TNBC. Inhibition of tumor protein P53 (TP53) has been demonstrated to increase the levels of cluster of differentiation 117 (CD117) in human colore...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Yanli, Huang, Wentao, Zhang, Huizhen, Liu, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876428/ https://www.ncbi.nlm.nih.gov/pubmed/29616097 http://dx.doi.org/10.3892/ol.2018.8104

Ejemplares similares

Limited importance of the dominant-negative effect of TP53 missense mutations
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2011)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
por: Hwang, Hye Jung, et al.
Publicado: (2020)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers
por: Zhang, Wensheng, et al.
Publicado: (2017)

p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma
por: Rodrigues, Joana M., et al.
Publicado: (2020)

Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma
por: Das, Sunetra, et al.
Publicado: (2021)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)

Comprehensive Analysis of the Prognostic Significance of the TRIM Family in the Context of TP53 Mutations in Cancers
por: Vu, Trung, et al.
Publicado: (2023)

Low density DNA microarray for detection of most frequent TP53 missense point mutations
por: Rangel-López, Angélica, et al.
Publicado: (2005)

Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma
por: Pain, Margaret, et al.
Publicado: (2017)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

Evaluating the prognostic significance of p53 and TP53 mutations in HPV-negative hypopharyngeal carcinoma patients: a 5-year follow-up retrospective study
por: Huang, Qiang, et al.
Publicado: (2023)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study
por: Yi, Dandan, et al.
Publicado: (2019)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients
por: Fernandez, Sandra V, et al.
Publicado: (2014)

Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations
por: Oros Klein, Kathleen, et al.
Publicado: (2016)

Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

PRIMA‐1 induces p53‐mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation
por: Furukawa, Haruna, et al.
Publicado: (2017)

Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

Prognostic significance of TP53 and PIK3CA mutations analyzed by next-generation sequencing in breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2023)

Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers and TP53 Mutation Status in Triple-Negative Cases
por: Sadzeviciene, Ieva, et al.
Publicado: (2022)

TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma
por: Zhou, Yiran, et al.
Publicado: (2023)

The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma
por: Omura, Go, et al.
Publicado: (2017)

Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene
por: Doffe, Flora, et al.
Publicado: (2020)

Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma
por: Lapke, Nina, et al.
Publicado: (2016)

Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases
por: Hurson, Amber N., et al.
Publicado: (2022)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Structural and functional implications of p53 missense cancer mutations
por: Tan, Yuhong, et al.
Publicado: (2009)

Significance of TP53 Mutational Status-Associated Signature in the Progression and Prognosis of Endometrial Carcinoma
por: Chen, Ying, et al.
Publicado: (2022)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Immunoexpression of CD34, CD117, and p53 in Hypocellular Bone Marrow Disorders
por: Sharma, Pooja, et al.
Publicado: (2021)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0p34oocrnnujmbhd2bdb8iufbb